Gkogkou Charalampos, Frangia Konstantina, Saif Muhammad W, Trigidou Rodoula, Syrigos Konstantinos
Pathology Department, "SOTIRIA" General Hospital, Athens, Greece.
Division of Hematology/Oncology, Tufts Medical Center, Boston, USA.
Springerplus. 2014 Mar 1;3:120. doi: 10.1186/2193-1801-3-120. eCollection 2014.
Necrosis and apoptosis represent two pathogenetically distinct types of cell death. Necrosis is associated with pathologic conditions while apoptosis is a physiological process of programmed cell death, which is associated with normal tissue growth and is frequently impaired in various forms of cancer. Tumor necrosis and apoptotic index (AI) have been previously evaluated as prognostic biomarkers in lung cancer, but their exact clinical value remains unclear. The aim of this study was to perform a systematic review of the MEDLINE literature on the prognostic significance of these histopathological markers in patients with non-small cell lung carcinoma (NSCLC). Although a substantial body of evidence suggests that tumor necrosis may be a strong predictor of aggressive tumor behavior and reduced survival in patients with NSCLC, the independent prognostic value of this biomarker remains to be firmly established. Furthermore, previous data on the prognostic significance of apoptotic index in NSCLC are relatively limited and largely controversial. More prospective studies are necessary in order to further validate tumor necrosis and AI as prognostic markers in NSCLC.
坏死和凋亡代表两种病理机制不同的细胞死亡类型。坏死与病理状况相关，而凋亡是程序性细胞死亡的生理过程，与正常组织生长相关，且在各种癌症中常受损。肿瘤坏死和凋亡指数（AI）先前已被评估为肺癌的预后生物标志物，但其确切的临床价值仍不清楚。本研究的目的是对MEDLINE文献进行系统综述，以探讨这些组织病理学标志物在非小细胞肺癌（NSCLC）患者中的预后意义。尽管大量证据表明肿瘤坏死可能是NSCLC患者侵袭性肿瘤行为和生存降低的有力预测指标，但该生物标志物的独立预后价值仍有待确定。此外，先前关于NSCLC中凋亡指数预后意义的数据相对有限且存在很大争议。需要更多的前瞻性研究来进一步验证肿瘤坏死和AI作为NSCLC预后标志物的价值。
